Geode Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Geode Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.8M	Buy	972,626 +168,974	+21%	+$4.99M	﹤0.01%	1849
2026 Q1	$18.5M	Buy	803,652 +50,133	+7%	+$1.13M	﹤0.01%	2034
2025 Q4	$15.2M	Buy	753,519 +37,231	+5%	+$775K	﹤0.01%	2162
2025 Q3	$13.2M	Buy	716,288 +120,270	+20%	+$2.36M	﹤0.01%	2247
2025 Q2	$13M	Sell	596,018 -18,505	-3%	-$384K	﹤0.01%	2183
2025 Q1	$11.4M	Buy	614,523 +18,341	+3%	+$449K	﹤0.01%	2209
2024 Q4	$15.9M	Sell	596,182 -983	-0.2%	-$28.2K	﹤0.01%	2083
2024 Q3	$14M	Buy	597,165 +362,221	+154%	+$8.22M	﹤0.01%	2174
2024 Q2	$4.36M	Buy	234,944 +9,895	+4%	+$176K	﹤0.01%	2814
2024 Q1	$4.02M	Buy	+225,049	New	+$4.54M	﹤0.01%	2814

Other funds holding AVBP

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management's AVBP Position: Q2 2026 in Review

Geode Capital Management increased its ArriVent BioPharma (AVBP) stake by 21% in Q2 2026, buying an estimated $4.99M and bringing the position to 972,626 shares worth $33.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1849.

Geode Capital Management first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 141 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Geode Capital Management held 972,626 shares of ArriVent BioPharma worth $33.8M as of Q2 2026.
Geode Capital Management bought 168,974 ArriVent BioPharma shares in Q2 2026, an estimated $4.99M.
ArriVent BioPharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1849 holding.
Geode Capital Management first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
141 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.